Fig. 7

Differences in response to immunotherapy between the high- and low-risk groups: (a) Expression levels of the top 15 immune checkpoint genes in the two risk score groups. (b) Expression levels of the top 15 HLA family genes in the two risk score groups. (c) Correlation between the TIDE dysfunction score and the risk score. (d) Correlation between the TIDE exclusion score and the risk score. (e) Drugs exhibiting differential sensitivity between the high-risk and low-risk groups. (f) Differences in the IPS between the high-risk and low-risk groups, reflecting varying responses to immunotherapy. Abbreviations: HLA: human leukocyte antigen; TIDE: tumor immune dysfunction and exclusion; IPS: immunophenoscore